Apogee Therapeutics, Inc.
APGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| R&D Expenses | $168 | $68 | $28 |
| G&A Expenses | $49 | $25 | $3 |
| SG&A Expenses | $49 | $25 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $217 | $93 | $31 |
| Operating Income | -$217 | -$93 | -$31 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $35 | $9 | -$9 |
| Pre-Tax Income | -$182 | -$84 | -$40 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$182 | -$84 | -$40 |
| % Margin | – | – | – |
| EPS | -3.3 | -1.66 | -0.79 |
| % Growth | -98.8% | -110.1% | – |
| EPS Diluted | -3.3 | -1.66 | -0.79 |
| Weighted Avg Shares Out | 55 | 51 | 51 |
| Weighted Avg Shares Out Dil | 55 | 51 | 51 |
| Supplemental Information | – | – | – |
| Interest Income | $35 | $9 | $0 |
| Interest Expense | $0 | $0 | $9 |
| Depreciation & Amortization | $0 | $9 | $0 |
| EBITDA | -$217 | -$75 | -$40 |
| % Margin | – | – | – |